02765cam a2200373 i 450000100090000000300040000900500170001300800410003001000170007102000280008803500130011604000280012904200080015705000240016508200160018910000210020524500240022625000110025026000320026130000430029333600210033633700250035733800230038250400510040550501200045652010530057652005930162965000310222265000190225365000200227270000310229270000240232370000440234717746819OSt20250925070933.0130521s2014    enka     b    001 0 eng    a  2013012165  a9780443112201qhardback  a17746819  aDLCbengcDLCerdadDLC  apcc00aRC268.4b.M675 201400a616.994223  aBocklage Therese00aMolecular oncology   a3rd ed  aPhiladephiabElsevierc2024  axix,969pbcolor illustrations ;c29 cm  atext2rdacontent  aunmediated2rdamedia  avolume2rdacarrier  aIncludes bibliographical references and index.8 aMachine generated contents note: Part I; Part II; Part III; Part IV. Pharmacologic Targeting of Oncogenic Pathways.  a"The genomic era has allowed enormous strides in our understanding of the molecular changes that underlie malignant transformation. Mutations have been discovered that are critical drivers of large cross-sections of human cancers. These discoveries have allowed us to find drugs that target these drivers and make important strides in treatment. Genomics and high-throughput technologies have illuminated the complexity of cancer and the facility with which cancers adapt during their natural history. The field is evolving rapidly with new discoveries and new drugs reported monthly. This book is a timely foundation for understanding in context the origins of molecular oncology and its future directions. The content reviews available technologies for the analysis of cancer tissues and genes; summaries of key oncogenic pathways from a molecular perspective; the technologies, pathways and targeted therapies of a wide range of human malignancies; and new pharmacologic therapies that have a common mechanistic target"--cProvided by publisher.  a"This book was conceived more than five years before its publication date. It was intended to provide a resource that summarized technology, biochemistry, molecular pathophysiology, and targeted therapeutics. As contributors were being recruited and chapters written the field that was being described changed at an accelerating pace. It is a tribute to scientific progress that volumes like this one are out-of-date as they are published, but books like this are not meant to contain the most current laboratory discovery or report the most recent FDA approval"--cProvided by publisher. 0aCancerxMolecular aspects. 0aTumor markers. 0aCarcinogenesis.1 aGelmann, Edward P.,d1953-1 aSawyers, Charles L.1 aRauscher, F. J.q(Frank Joseph),d1957-